AFT announces successful completion of Placement

103372.5 - 1142646-1







Not for release to US wire services or distribution to the US

Market and Media release 11
th
June 2020

AFT Pharmaceuticals announces successful completion of Placement
AFT Pharmaceuticals Limited (NZX:AFT/ASX:AFP) (AFT) is pleased to announce the
successful completion of its NZ$73.8 million Placement (Placement), comprising a
NZ$10 million primary issuance and a sell down by certain major shareholders of
NZ$63.8 million of existing shares.
Approximately 19.7 million shares were sold to existing shareholders and new
investors across the Placement, including approximately 2.7 million new shares under
the primary issuance, at a price of NZ$3.75 per share. The Placement price
represents a discount of 11.1% to the 30-day VWAP up to 9 June of NZ$4.22 and a
discount of 20.2% to the last close price of NZ$4.70 on 9 June 2020.
AFT Founder and Chief Executive Hartley Atkinson said: “We are pleased with the
response we have had to the Placement and look forward to offering shares to our
existing retail investors with the upcoming Share Purchase Plan (SPP).
“In addition to the strong takeup of the Placement from New Zealand investors, we
are delighted to be welcoming a broad swathe of Australian institutional and retail
investors onto our share register. Through the placement, sell downs and SPP the free
float of the company is expanding from 11% to up to 31% of the shares on issue.
“We are hopeful the addition of these new investors - coupled with our record of
strong growth and consistently delivering on market expectations – will help to build
AFT’s profile and a deeper appreciation for the significant opportunities we enjoy in
Australasia and further afield.”
Settlement of the Placement is expected to occur on 15
th
June 2020. The new
shares issued under the Placement are expected to be allotted and commence
trading on the NZX and ASX on 15
th
June 2020, and will rank equally in all respects
with AFT’s existing ordinary shares.
Share Puchase Plan
As announced on 10
th
June 2020, AFT is also undertaking a NZ$2 million share
purchase plan (SPP). Full details of the SPP will be set out in the SPP offer document,

103372.5 - 1142646-1
Pg. 2

which is expected to be released to NZX and ASX and dispatched to eligible
shareholders on 15
th
June 2020. Key dates relating to the SPP are set out below.



Key Dates for the SPP
1

SPP Record Date 7pm NZT, Tuesday 9
th
June 2020
SPP Opens Monday 15
th
June 2020
SPP Closes Friday 26
th
June 2020
Allotment of shares Thursday 2
nd
July 2020
Commencement of trading of the new
shares on NZX
Thursday 2
nd
July 2020
Commencement of trading of the new
shares on ASX
Friday 3
rd
July 2020

Additional information
Further details about the Placement and the SPP are set out in the announcment
and investor presentation released to the NZX and ASX on 10
th
June 2020.

- Released for and on behalf of AFT Pharmaceuticals limited by Chief Financial Officer Malcolm Tubby
For more information
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals +64 21 645 643
Tel: +64 9 488 0232


About AFT Pharmaceuticals

1
The timetable presented is indicative only and subject to change without notice (subject to applicable laws and the NZX Listing
Rules and ASX Listing Rules).

103372.5 - 1142646-1
Pg. 3

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad
portfolio of pharmaceutical products across a wide range of therapeutic categories which are
distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription
and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes
patented, branded and generic drugs. Our business model is to develop and in-license products for sale
by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain
Southeast Asian markets, and to out-license our products to local licensees and distributors to the rest of
the world.


Not for release or distribution in the United States
This announcement has been prepared for publication in New Zealand and Australia and may not be
released to US wire services or distributed in the United States. This announcement does not constitute an
offer of securities for sale in the United States or any other jurisdiction. Any securities described in this
announcement may not be offered or sold in the United States absent registration under the US Securities
Act of 1933 or an exemption from registration.